Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,088 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Quon HC, et al. Among authors: ong a. Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15. Radiother Oncol. 2018. PMID: 29551231 Clinical Trial.
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC. Roy S, et al. Among authors: ong a. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21. Clin Oncol (R Coll Radiol). 2019. PMID: 31126725
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A. Alayed Y, et al. Among authors: ong a. Radiother Oncol. 2019 Nov;140:105-109. doi: 10.1016/j.radonc.2019.06.018. Epub 2019 Jun 29. Radiother Oncol. 2019. PMID: 31265940
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.
Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Liu SK, Panjwani D, Helou J, Musunuru HB, Pang G, Korol R, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, D'Alimonte L, Ho L, Bhounr Z, Loblaw A. Alayed Y, et al. Among authors: ong a. Radiother Oncol. 2020 Mar;144:135-140. doi: 10.1016/j.radonc.2019.11.017. Epub 2019 Dec 3. Radiother Oncol. 2020. PMID: 31809979
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
Alayed Y, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Alayed Y, et al. Among authors: ong a. Radiother Oncol. 2020 Aug;149:8-13. doi: 10.1016/j.radonc.2020.04.039. Epub 2020 Apr 27. Radiother Oncol. 2020. PMID: 32416376 Clinical Trial.
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Kim JO, McDonald MO, Ong A, Koul R, Dubey A, Hunter W, Ahmed S, Quon H, Yee D, Parliament M, Sivananthan G, Danielson B, Rowe L, Ghosh S, Usmani N. Kim JO, et al. Among authors: ong a. Radiat Oncol. 2021 Nov 4;16(1):212. doi: 10.1186/s13014-021-01935-x. Radiat Oncol. 2021. PMID: 34736499 Free PMC article. Clinical Trial.
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N, Ghosh S, Sanghera KP, Ong AD, Koul R, Dubey A, Ahmed S, Quon H, Yee D, Parliament M, Sivananthan G, Hunter W, Danielson B, Rowe L, McDonald M, Kim JO. Usmani N, et al. Among authors: ong ad. Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):317-326. doi: 10.1016/j.ijrobp.2022.07.035. Epub 2022 Jul 28. Int J Radiat Oncol Biol Phys. 2023. PMID: 35907513 Clinical Trial.
1,088 results